Qube Research & Technologies LTD Athira Pharma, Inc. Transaction History
Qube Research & Technologies LTD
- $82.3 Billion
- Q1 2025
A detailed history of Qube Research & Technologies LTD transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 221,068 shares of ATHA stock, worth $61,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
221,068
Previous 350,007
36.84%
Holding current value
$61,899
Previous $206,000
70.39%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ATHA
# of Institutions
61Shares Held
18.4MCall Options Held
14.3KPut Options Held
4.4K-
Perceptive Advisors LLC New York, NY5.4MShares$1.51 Million0.06% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.2MShares$896,1860.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.54MShares$430,6150.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$417,9810.49% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$417,9810.02% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $10.6M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...